Search Results
Results found for "LASEREDD Therapeutics"
- Sam Hoare: Receptor Residence Time and GPCR Data Analysis | Dr. GPCR Ecosystem
company supporting pharmaceutical, life science, and academic scientists in the development of new therapeutics analysis of drug action and is known for applying binding kinetics to the development of effective therapeutics
- Dr. John Streicher: Reorganizing Opioid Signaling Beyond the Receptor | Dr. GPCR Ecosystem
Current lines of work include isoform-selective HSP90 inhibition as a strategy for widening the opioid therapeutic This is not a quirk — it is the central clue the lab has built a therapeutic strategy around.
- Brian Arey - Part 2: GPCR Drug Discovery and the Science Nobody Publishes | Dr. GPCR Ecosystem
GPR56 as a mechanical sensor and his sustained case for the KLF2 signaling pathway as a GPCR-linked therapeutic His recently published book on signaling bias, Biased Signaling in Physiology, Pharmacology, and Therapeutics
- Kathryn Livingston: Allosteric Opioid Modulators and Receptor Signaling Beyond the Membrane | Dr. GPCR Ecosystem
Themes of the Conversation Allosteric modulation of opioid receptors - mechanism, selectivity, and therapeutic The therapeutic logic is that decoupling from the orthosteric site might preserve pain relief while altering
- Brian Arey: Discovering Signaling Bias at the FSH Receptor | Dr. GPCR Ecosystem
He argues for a therapeutic strategy built around modulators that can be combined, rather than single His recently published book on signaling bias, Biased Signaling in Physiology, Pharmacology, and Therapeutics
- Kari Johnson: mGlu2, Addiction, and the Brain Circuits Alcohol Rewires | Dr. GPCR Ecosystem
modulate drug seeking, habit formation, and reward processing - and has been pursued as a potential therapeutic adolescent alcohol exposure disrupts mGlu2 function in the striatum in a way that might seem to close off therapeutic
- Qing Fan: Inside the Architecture of Class C GPCRs | Dr. GPCR Ecosystem
mutations in the GABA-B transmembrane domain and what they suggest about precision pharmacology The therapeutic But its therapeutic window is narrow.
- Our History | Dr. GPCR Ecosystem
Sep 20, 2022 — First contributor article published: Therapeutic validation of an orphan G protein‐coupled
- Scaling GLP 1 Receptor Tools Through Academia Industry Collaboration | Dr. GPCR Ecosystem
By integrating advanced tools and translational biology, his work directly informs therapeutic strategies
- GPCR Webinars | Dr. GPCR Ecosystem
Each session explores mechanistic models, translational challenges, and real-world therapeutic implications
- GPCRs and the Science Behind Pain and Recovery with Dr. Alex Serafini | Dr. GPCR Ecosystem
analysis, revealed nuanced roles of RGS4, RGS9, and RGSZ — not just as modulators but as potential therapeutic
- When to Walk, When to Run: Lessons from the GPCR Trenches with Dr. Ben Clements | Dr. GPCR Ecosystem
Clements' work is primarily focused on translational developments of small molecule therapeutics, and
- Hacking GPCRs: Tools, Tech & Drug Discovery with Tom Sakmar & Ilana Kotliar | Dr. GPCR Ecosystem
This could accelerate discovery of therapeutic targets by combining multiplex data with focused downstream
- Silvio Gutkind: When GPCRs Drive Cancer | Dr. GPCR Ecosystem
The canonical assumption that targeting PLC would be therapeutic has failed in the clinic, and patients
- Aaron Sato: Synthetic Antibody Libraries for the Hardest GPCR Targets | Dr. GPCR Ecosystem
record as a biologics leader as he led teams to discover and develop novel first-in-class antibody therapeutics
- Amynah Pradhan: The Delta Opioid Receptor and the Migraine Paradox | Dr. GPCR Ecosystem
Andrew Charles that who specialized in animal models of migraine and delta-opioid receptors as a therapeutic
- Joseph Kim: Structural Biology and Drug Discovery at GPCRs | Dr. GPCR Ecosystem
structural biology and drug discovery, where molecular structures inform the design and development of new therapeutics You could easily imagine separate therapeutic programs targeting those different physiological effects
- Foord: Serendipity, RAMPs, And Industrial GPCR Pharmacology | Dr. GPCR Ecosystem
Later hepatotoxicity concerns and the success of antibody therapeutics further shifted strategy.
- Debbie Hay: Class B GPCRs, RAMPs, and the Migraine Pharmacology Gap | Dr. GPCR Ecosystem
to produce a distinct complex - different ligand selectivity, different signaling profile, different therapeutic
- Yamina Berchiche: Beyond the Lab — From Chemokine Receptors to the Dr. GPCR Ecosystem | Dr. GPCR Ecosystem
has reached only about 166 of them, leaving more than 250 receptors unstudied at anything close to therapeutic
- Masha Niv: Bitter Taste Receptors and the Drug Discovery Blind Spot | Dr. GPCR Ecosystem
activation, and resistant to pharmacological blockade - and why those properties have shaped both the therapeutic
- Michel Bouvier: BRET, Biased Agonism, and the Tools That Changed GPCR Pharmacology | Dr. GPCR Ecosystem
of Canada (2014), the Julie Axelrod award from the American Society of Pharmacology and Exerimental Therapeutics
- David Gloriam: Orphan Receptors, GPCRDB, and the Data Revolution in GPCR Pharmacology | Dr. GPCR Ecosystem
symptomatic of a deeper challenge: the field has not yet fully characterized which signaling pathways produce therapeutic
- Revvity | Dr. GPCR Ecosystem
Whether you’re decoding signaling pathways or designing the next generation of therapeutics, Revvity
- Anita Nivedha: Computational Dynamics of Ligand Bias in GPCR Signaling | Dr. GPCR Ecosystem
visualization to become quantitative tools for understanding receptor activation and guiding GPCR-targeted therapeutics
























